All In Biotech

Drug Trial Radar · NCT06153966

PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patients With Prion Disease

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

85

Actual

Start

Jan 4, 2024

Primary completion

Apr 2027

Study completion Aug 2030

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Dec 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.

Conditions

  • Prion Disease

Interventions

  • ION717Drug

    ION717 will be administered by IT injection.

  • PlaceboDrug

    Placebo-matching ION717 will be administered by IT injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events.Time frame: Baseline up to Week 33

Locations

13 sites in 9 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • NYU Langone Health

    New York, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Royal Melbourne Hospital

    Parkville, Australia

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Hôpital Universitaire Pitié Salpêtrière

    Paris, France

  • University Medical Center Göttingen

    Göttingen, Germany

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

    Milan, Italy

  • Mihara Memorial Hospital

    Gunma, Isesaki-shi, Japan

  • National Center of Neurology and Psychiatry

    Tokyo, Kodaira-shi, Japan

  • Neuromuscular Center Yoshimizu Hospital

    Yamaguchi, Shimonoseki-shi, Japan

  • Hospital Clinic De Barcelona

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.